Free Trial
NASDAQ:RGEN

Repligen (RGEN) Stock Price, News & Analysis

Repligen logo
$127.36 +0.40 (+0.32%)
Closing price 07/3/2025 01:10 PM Eastern
Extended Trading
$127.36 0.00 (0.00%)
As of 07/3/2025 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Repligen Stock (NASDAQ:RGEN)

Key Stats

Today's Range
$126.49
$129.11
50-Day Range
$117.54
$143.63
52-Week Range
$102.97
$182.52
Volume
208,766 shs
Average Volume
729,442 shs
Market Capitalization
$7.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$172.83
Consensus Rating
Moderate Buy

Company Overview

Repligen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

RGEN MarketRank™: 

Repligen scored higher than 96% of companies evaluated by MarketBeat, and ranked 55th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Repligen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Repligen's stock forecast and price target.
  • Earnings Growth

    Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Repligen is -283.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Repligen is -283.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Repligen has a PEG Ratio of 3.65. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Repligen has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Repligen's valuation and earnings.
  • Percentage of Shares Shorted

    6.38% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Repligen has recently decreased by 1.74%, indicating that investor sentiment is improving.
  • Dividend Yield

    Repligen does not currently pay a dividend.

  • Dividend Growth

    Repligen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.38% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Repligen has recently decreased by 1.74%, indicating that investor sentiment is improving.
  • News Sentiment

    Repligen has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Repligen this week, compared to 9 articles on an average week.
  • Search Interest

    Only 2 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Repligen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Repligen is held by insiders.

  • Percentage Held by Institutions

    97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Repligen's insider trading history.
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

Repligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to "Hold"
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Repligen (NASDAQ:RGEN) Coverage Initiated at Barclays
Repligen: Long-Term Growth Gem Suffers Some Setbacks
See More Headlines

RGEN Stock Analysis - Frequently Asked Questions

Repligen's stock was trading at $143.94 at the beginning of 2025. Since then, RGEN shares have decreased by 11.5% and is now trading at $127.36.

Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, April, 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The company's revenue was up 10.4% compared to the same quarter last year.
Read the conference call transcript
.

Repligen subsidiaries include these companies: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others.

Repligen's top institutional investors include Harbor Investment Advisory LLC. Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax.
View institutional ownership trends
.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
4/29/2025
Today
7/05/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGEN
Employees
1,778
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$172.83
High Stock Price Target
$200.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+35.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
74.05
P/E Growth
3.65
Net Income
-$25.51 million
Pretax Margin
-3.53%

Debt

Sales & Book Value

Annual Sales
$634.44 million
Cash Flow
$3.10 per share
Price / Cash Flow
41.03
Book Value
$35.21 per share
Price / Book
3.62

Miscellaneous

Free Float
55,509,000
Market Cap
$7.16 billion
Optionable
Optionable
Beta
1.11

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:RGEN) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners